GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » EV-to-FCF
中文

Oncodesign Precision Medicine (XPAR:ALOPM) EV-to-FCF

: (As of Today)
View and export this data going back to 2022. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Oncodesign Precision Medicine's Enterprise Value is €28.44 Mil. Oncodesign Precision Medicine does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022. Therefore, GuruFocus does not calculate Oncodesign Precision Medicine's EV-to-FCF at this moment.

The historical rank and industry rank for Oncodesign Precision Medicine's EV-to-FCF or its related term are showing as below:

XPAR:ALOPM's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 4.27
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-23), Oncodesign Precision Medicine's stock price is €1.525. Oncodesign Precision Medicine does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022. Therefore, GuruFocus does not calculate Oncodesign Precision Medicine's PE Ratio at this moment.

Oncodesign Precision Medicine EV-to-FCF Historical Data

The historical data trend for Oncodesign Precision Medicine's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
EV-to-FCF
- -

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22
EV-to-FCF - - -
Competitive Comparison

For the Biotechnology subindustry, Oncodesign Precision Medicine's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncodesign Precision Medicine EV-to-FCF Distribution

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's EV-to-FCF falls into.


Oncodesign Precision Medicine EV-to-FCF Calculation

Oncodesign Precision Medicine's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=28.435/
=

Oncodesign Precision Medicine  (XPAR:ALOPM) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Oncodesign Precision Medicine's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.525/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Oncodesign Precision Medicine EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » EV-to-FCF
Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Website
https://www.opm.oncodesign.com
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines